/
OmniAb, Inc. licenses cutting-edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners drug development efforts.
The business is unprofitable at the operating level (-369.49% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 29.3% YoY. Margins deteriorated 87.2pp alongside, both lines moving the wrong way.
Negative free cash flow of -$37M. The business is consuming cash, not generating it. Operating margin contracted 87.2pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (TTM)
$29M
▼ -29.3% YoY
Net Income (TTM)
-$54M
▼ -4.4% YoY
Op. Margin
-200.26%
▼ -87.2pp YoY
ROIC
-15.90%
▼ -0.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$26M
▲ +10.9% YoY
Op. Cash Flow (TTM)
-$25M
▲ +8.1% YoY
Net Debt
-$29M
Net Cash Position
Cash & Equiv.
$49M
3Y CAGR: -31.9%
Continue Research